TIFFANY DUPREE: Open Payments
NPI 1467904557 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,975 in 75 payments from 14 companies in 2025. Trend: 2023 $814 · 2024 $895 · 2025 $1,975
Food & beverage: $1,876Education: $100
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $370 |
| Teva Pharmaceuticals USA, Inc. | 9 | $329 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $294 |
| Braeburn Inc. | 7 | $208 |
| Supernus Pharmaceuticals, Inc. | 6 | $129 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $118 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $113 |
| ABBVIE INC. | 5 | $87 |
| Janssen Pharmaceuticals, Inc | 3 | $65 |
| Neurocrine BioSciences, Inc. | 3 | $63 |
Products named: REXULTI, CAPLYTA, AUSTEDO XR, BRIXADI, Qelbree, Kerendia, VRAYLAR, SPRAVATO.
Industry payments across AL — which companies pay providers there.
